A5003133664- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Complement system in diseases
- Acute Myeloid Leukemia Research
- Renal Transplantation Outcomes and Treatments
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- GDF15 and Related Biomarkers
- Acute Lymphoblastic Leukemia research
- Renal Diseases and Glomerulopathies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Neutropenia and Cancer Infections
- Mesenchymal stem cell research
- Biomedical Ethics and Regulation
- Cystic Fibrosis Research Advances
- Antifungal resistance and susceptibility
- Neurological Complications and Syndromes
- Pneumocystis jirovecii pneumonia detection and treatment
- Mycobacterium research and diagnosis
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- Childhood Cancer Survivors' Quality of Life
G. Papanikolaou General Hospital
2016-2025
Alexion Pharma (Switzerland)
2020
European Hematology Association
2020
Abstract Renewed interest has emerged in transplant‐associated thrombotic microangiopathy ( TA ‐ TMA ) with novel prognostic, diagnostic, and treatment algorithms. We aimed to investigate the incidence, prognostic factors, morbidity, mortality of allogeneic hematopoietic cell transplantation HCT recipients. enrolled consecutive recipients (1990‐2017). Among 758 patients, 116 (15.5%) were diagnosed . In multivariate analysis, TBI ‐based conditioning, viral infections, acute chronic GVHD...
Loss of microbiota diversity has been clearly associated with poor outcomes in the allogeneic hematopoietic stem cell transplantation setting. However, choice optimal antibiotic prophylaxis during pre-engraftment phase remains unclear. We designed a prospective randomized study to compare our standard-of-care neutropenia (ciprofloxacin) rifaximin. enrolled 38 consecutive adult patients who underwent setting and were randomly assigned receive ciprofloxacin (20 patients) or rifaximin (18 at...
Transplant-associated thrombotic microangiopathy (TA-TMA) and graft-versus-host disease (GVHD) are complications of allogeneic hematopoietic cell transplantation (HCT) that share several common characteristics.1 Both affect multiple organs lead to significant morbidity mortality despite optimal management. Despite a distinct clinical phenotype, both manifest in the early posttransplant period have denominator: endothelial damage.2 Endothelial injury has been long recognized as contributor...
(1) Background: Autologous, allogeneic hematopoietic cell transplantation (HCT) and other cellular therapies, including CAR T gene therapy, constitute a cornerstone in the management of various benign malignant hematological disorders. Invasive fungal infections (IFD) remain significant cause morbidity mortality HCT recipients. Therefore, we investigated prevalence risk factors IFD following therapies an era novel antifungal prophylaxis. (2) Methods: In this study, retrospectively enrolled...
Endothelial injury indices, such as Activation and Stress Index (EASIX), modified EASIX (m-EASIX), simplified (s-EASIX) scores, have been previously associated with chimeric antigen receptor-T (CAR-T) cell immunotherapy complications. Soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation factor-15 (GDF-15), soluble C5b-9 (sC5b-9) described markers of endothelial post-hematopoietic stem transplantation. In the current study, we examined whether suPAR, GDF-15,...
This retrospective study aimed to describe the Hellenic experience on use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 April 2015, ninety-five patients with R/R HL, who received BV 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% males. Sixty-seven after autologous stem cell transplantation failure, whereas 28 treated without a prior transplantation, due advanced age/comorbidities or...
Changes in gut microbiome composition have been implicated the pathogenesis of graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our objective was to explore microbial abundance patients with GvHD allo-HSCT. We conducted a single-center, prospective study who underwent allo-HSCT and developed grade II or higher acute and/or moderate severe chronic GvHD, taxa at phylum, family, genus, species level, we utilized alpha beta diversity indices...
Limited and conflicting data exist on outcomes of patients with extramedullary relapses (EMRs) after allogeneic hematopoietic cell transplantation (allo-HCT) for acute leukemias. We retrospectively reviewed charts consecutive allo-HCT recipients who underwent in our center the indication leukemia (July 1990 to July 2018). Incidences isolated EMR (iEMR) bone marrow relapse (BMR) were calculated using cumulative incidence (CI) analysis, each treatment-related mortality considered a competing...
(1) Background: survivors of allogeneic hematopoietic cell transplantation (alloHCT) suffer from morbidity and mortality due to cardiovascular events. We hypothesized that vascular injury pro-coagulant activity are evident in alloHCT without existing complications or relapse. (2) Methods: we enrolled consecutive adult established disease control individuals matched for traditional risk factors (January–December 2019). Circulating microvesicles (MVs) different cellular origins (platelet,...
Commercially available anti-CD19 chimeric antigen receptor T cells (CARΤ cells) have offered long-term survival to a constantly expanding patient population. Given that novel toxicities including cytokine release syndrome (CRS) and neurotoxicity (ICANS) been observed, we aimed document the safety toxicity of this treatment in real-world study. We enrolled 31 adult patients referred our center for CAR therapy. Tisagenlecleucel was infused 12 patients, axicabtagene ciloleucel 14,...
Despite novel biological agents, steroid-dependent or -refractory graft-versus-host disease (GvHD) remains a severe complication of allogeneic hematopoietic cell transplantation (allo-HCT). Extracorporeal photopheresis (ECP) is an alternative, non-immunosuppressive treatment for patients with acute (aGvHD) chronic (cGvHD) GvHD. The aim this study was to investigate the safety and efficacy ECP in GvHD;
Transplant-associated thrombotic microangiopathy (TMA) occurs in a significant percentage of patients after allogeneic stem cell transplantation (allo-SCT) and is associated with morbidity mortality. The aim the present study was to examine association serum angiopoetin-2 (Ang2) levels presence antibodies against angiotensin II type 1 (AT1R) ndothelin A Recreptor (ETAR) outcome TMA and/or graft-versus-host disease (GVHD) allo-SCT. Analysis our data showed that elevated Ang2 at time diagnosis...
Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) and graft-versus-host disease (GvHD) represent life-threatening syndromes after allogeneic hematopoietic transplantation (allo-HSCT). In both conditions, endothelial dysfunction is a common denominator, development of relevant biomarkers high importance for diagnosis prognosis. Despite the fact that soluble urokinase plasminogen activator receptor (suPAR) growth differentiation factor-15 (GDF-15) have...
Abstract The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) after autologous stem cell transplantation (auto‐SCT) is poor. Recently, the anti‐CD30 monoclonal antibody‐drug conjugate, brentuximab vedotin (BV), has shown remarkable activity in setting R/R cHL. In pivotal phase II study, BV produced an overall response rate 75% and a median progression‐free survival 6.7 months. Although these results have been reproduced by large registry studies, impact on...
We have previously shown an advantage of a myeloablative conditioning regimen with reduced toxicity (Fludarabine 150 mg/m2, Treosulfan 42 g/m2, FluTreo) compared to reduced-intensity regimen. aimed determine long-term safety and efficacy FluTreo. prospectively studied consecutive patients who received FluTreo in our center (2014-2019) on the basis age (≥50 years), hematopoietic cell transplantation comorbidity index (HCT-CI) ≥2, or both. recipients were then historical control group. 68...